A detailed history of Amundi transactions in Allakos Inc. stock. As of the latest transaction made, Amundi holds 75,686 shares of ALLK stock, worth $87,795. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,686
Previous 75,686 -0.0%
Holding current value
$87,795
Previous $75,000 34.67%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.0 - $1.45 $7,044 - $10,213
-7,044 Reduced 8.51%
75,686 $75,000
Q4 2023

Feb 14, 2024

BUY
$1.72 - $3.18 $142,295 - $263,081
82,730 New
82,730 $225,000
Q1 2022

May 16, 2022

SELL
$5.08 - $9.81 $9,108 - $17,589
-1,793 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$85.37 - $114.1 $153,068 - $204,581
1,793 New
1,793 $153,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $98.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.